This video is basically a “big‑picture” debrief of ASH 2025 in multiple myeloma, aimed at people in pharma and biotech rather than front‑line clinicians. It walks through the most important new data on bispecifics, CAR‑T, trispecifics, gene and targeted therapies, and combos like Tec‑Dara, and explains how they could change standard treatment across different disease stages. On top of the science, it also talks about how big and fast‑growing the MM market is, what regulators are doing, how crowded the field is, and what people are saying on social media, to help teams spot opportunities, partnerships, and portfolio moves